Studying UBT251 for MASH liver disease
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have MASH diagnosed by liver biopsy, with moderate liver scarring (stage F2 or F3).
- Your liver fat on an MRI scan must be at least 8%.
- You need at least one of these: overweight, large waist, high blood pressure, high triglycerides, low 'good' cholesterol, or high blood sugar/diabetes.
- You cannot have used GLP-1 medications (like Ozempic) in the last 3 months.
- You must be willing to have a liver biopsy and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
This trial tests an experimental gene therapy (VV-14303) given as a single injection into the muscle to treat MASH, a common type of fatty liver disease with inflammation. The study will check if the treatment is safe and helps improve liver health.
This trial tests an experimental drug for people with a type of fatty liver disease called MASH that has led to liver scarring. The goal is to see if the drug can help reduce liver damage and improve liver health.
This study tests an investigational medicine called pemvidutide to see if it can reduce liver scarring in people with MASH (a liver condition linked to excess weight and metabolic issues). It may help improve liver health and potentially slow or reverse the condition.
Hear when a new Metabolic Dysfunction-associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.